01.26.26 -- The Metaphoric Rise Of Outsourcing

Taking a molecule from drug substance to drug product often falters at the handoff. In this webinar, KBI Biopharma and Argonaut Manufacturing Services share how integrated CDMO-to-fill-finish partnerships eliminate silos, streamline quality, and reduce risk. Join a candid fireside chat on the top 10 quality challenges and proven solutions that cut timelines by 2–3 months from development through late-stage commercialization. Click here to learn more.

Explore innovative strategies in process intensification to boost mAb production and hear from industry experts as they share solutions for scaling efficiency and navigating regulatory challenges.

Controlled nucleation standardizes freezing across all vials, leading to uniform ice crystals and improved lyo cake quality. This critical step reduces variability and supports robust product scale-up.

Learn how AI is transforming the biomanufacturing industry and how partnerships between pharmaceutical companies and academic institutions are poised to set the new standard.

GlycoNex's denosumab biosimilar development experience illustrates how a "just copy it" approach is an insufficient strategy in modern biomanufacturing.

Embrace the future of drug development by leveraging AI and innovative protein synthesis technologies to accelerate the creation of effective therapies and transform patient outcomes.

Discover how diagnosing ribosome pausing sites and optimizing codon usage dramatically improves bispecific antibody titers, turning difficult-to-express candidates into viable therapeutics.

Uncover the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug-delivery systems.

Leveraging cross-functional coordination between sites, tech transfers, one quality system, and synchronized team activities can streamline submissions and deliver high-quality commercial outcomes.

Observe how integrated project management and co-located DS/DP operations streamline technology transfer, reduce risks, and accelerate biopharmaceutical development timelines.

See the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.

Successful development of AOCs for FIH studies requires robust GMP processes and efficient scale-up. A key step is careful management of a multi-day conjugation process with vital in-process checks.

This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions. Click here to learn more.

Biosafety testing ensures biologics' safety and quality but faces challenges like cost, time, and technical complexity. Proper planning and regulatory compliance are key to success.

View expert aseptic manufacturing with flexible batch sizes, regulatory excellence, and end-to-end support, specializing in sterile injectable solutions for clinical and commercial needs.

Partner with a global network of cGMP-certified mammalian cell culture manufacturing facilities to ensure scalable, high-quality biologics production and seamless global supply.

Accelerate your time to market and minimize the risk of choosing components that may not integrate well by opting for a fully coordinated containment solution.

Successful development relies on a deep understanding of a molecule’s unique characteristics. We have the knowledge and expertise to realize the true potential of your molecule, regardless of its complexity.

Leverage integrated platforms for targeted protein degradation and molecular glue solutions, from ligand identification to IND-enabling studies.